William Blair analyst Matt Larew has maintained their bullish stance on TKNO stock, giving a Buy rating on March 3.
Matt Larew has given his Buy rating due to a combination of factors including Alpha Teknova’s consistent top-line momentum and profitability improvements. The company’s fourth-quarter results showed a revenue increase of 17.8% year-over-year, slightly surpassing both the firm’s and consensus estimates. Despite some minor variances in specific segments, the overall performance was strong, with Clinical Solutions revenue significantly exceeding expectations.
Looking ahead, Teknova’s 2025 guidance suggests continued growth, with projected revenue between $39 million and $42 million, driven by both its catalog and custom biopharma businesses. The company anticipates gross margins to improve and free cash flow to exceed previous estimates, indicating effective cost control measures. Although there is some macroeconomic uncertainty affecting the biopharma market, Teknova’s strategic positioning and financial outlook support the Buy recommendation.
According to TipRanks, Larew is an analyst with an average return of -9.4% and a 40.00% success rate. Larew covers the Healthcare sector, focusing on stocks such as Amedisys, Repligen, and Option Care Health.
Questions or Comments about the article? Write to editor@tipranks.com